Main news

Dear colleagues! The Forum organizing committee informs you about the acceptance of reports / symposia and abstracts for publication.


 

 

CONFERENCE NEWS

https://www.medscape.com/viewcollection/34963


 

Expert point of view
Expert point of view Strategies to Overcome Residual Risk During Statins Era



PreHT 2020|Vilnius | Lithuania | 2-5 April 2020 7th International Conference on Prehypertension, Hypertension, Metabolic Disorders and Cardiovascular Disease (PreHT 2020)


Editorial Activity

cardiology book


FDA Clears Architect Stat High-Sensitivity Troponin Test for MI
FDA Clears Architect Stat High-Sensitivity Troponin Test for MI The US Food and Drug Administration (FDA) has approved the Architect Stat (Abbott Laboratories) high-sensitivity troponin-I assay, which can detect myocardial infarction (MI) faster and more accurately than other troponin tests, according to the company.


World Heart Day 2019
World Heart Day 2019 This year on World Heart Day, as part of our mission to ensure heart health equity for all, we want to create a global community of Heart Heroes … people from all walks of life who are acting now to live longer, better, heart-healthy lives by making a promise: for MY HEART, for YOUR HEART, for ALL OUR HEARTS.


ESC 2019: Wrap up in Russian - Live and interactive programme
ESC 2019: Wrap up in Russian - Live and interactive programme In collaboration with the Russian Society of Cardiology, this programme is designed to present a selection of scientific highlights from ESC Congress and discuss clinical practice implications with experts.


ESC Congress 2019                      together with World Congress of Cardiology
ESC Congress 2019 together with World Congress of Cardiology ESC Congress 2019 together with World Congress of Cardiology Saturday 31 August - Wednesday 4 September 2019 Paris - France


Announcement of the European Congress of Cardiology
Announcement of the European Congress of Cardiology From August 31 to September 4, 2019, he Congress of the European Society of Cardiology in conjunction with the World Congress of Cardiology - will be held in Paris (France).


Trial Evaluating Sacubitril/Valsartan for HFpEF Misses Primary End Point
Trial Evaluating Sacubitril/Valsartan for HFpEF Misses Primary End Point Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).


ESC Congress 2019                      together with World Congress of Cardiology
ESC Congress 2019 together with World Congress of Cardiology Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).